Figure 8.
FGFR1 overexpression in T47D cells induces resistance to palbociclib-mediated inhibition, with modified signaling in RTK, ER, and LRP6 pathways. (A) FGFR1 protein levels in T47D/C and T47D/FGFR1 cells. (B) T47D/C and T47D/FGFR1 cells were treated with palbociclib (0–40 µM) for 5 days, followed by an XTT assay. Survival fractions and IC50 values based on data of 8 replicates were analyzed with Prism 7. (C,D) Clonogenic assays of T47D/C and T47D/FGFR1 cells treated with palbociclib. The cells, in triplicate, were treated with palbociclib (0, 5, 10 μM) for 2 weeks. The colonies were stained with crystal violet and quantified. The data were statistically analyzed with Student’s t-test (** p < 0.01). (E) Western blot detection of indicated markers of relevant pathways in T47D/C and T47D/FGFR1 cells treated with palbociclib. The cells were treated at indicated concentrations for 48 h, followed by Western blot analysis of specified markers.